Understanding Nanoparticle Uptake by Human Corneal Epithelial Cells: Implications for Ocular Drug Delivery

Study Background and Research Question

Ocular diseases present persistent challenges in drug delivery due to the unique protective barriers of the eye. Conventional topical ophthalmic formulations, while widely used, suffer from poor bioavailability largely because of rapid clearance by the tear film and limited penetration across the cornea. The corneal epithelium, although comprising only about 10% of the corneal thickness, is responsible for 90% of its barrier function. This complex barrier hampers efficient delivery of therapeutic agents to intraocular tissues, necessitating new strategies for enhancing drug uptake and retention. In this context, polymeric nanoparticles have emerged as promising vehicles for ocular therapeutics, but fundamental questions remain regarding how their size and surface properties influence their interaction and uptake by corneal cells. The reference study (Azadi & David, 2024) specifically addresses these questions, probing the mechanistic aspects of nanoparticle-cell interactions in a controlled in vitro human corneal epithelial cell (HCEC) model.

Key Innovation from the Reference Study

The primary innovation of this research lies in its systematic dissection of the size- and surface chemistry-dependent uptake mechanisms of poly(lactic-co-glycolic acid) (PLGA) nanoparticles by HCECs. Unlike prior studies that often focused on in vivo outcomes or bulk pharmacokinetics, this work utilizes a physiologically relevant in vitro model to precisely map endocytic pathways. By employing surface modifications with mucoadhesive (alginate and chitosan) and mucopenetrative (polyethylene glycol, PEG) polymers, the authors were able to study how subtle differences in nanoparticle characteristics modulate cellular uptake routes. Furthermore, the application of multiple pathway-specific inhibitors provided direct mechanistic evidence for the predominant endocytic processes involved.

Methods and Experimental Design Insights

PLGA nanoparticles were synthesized via the emulsion-solvent evaporation method, producing monodisperse, spherical particles with polydispersity indices (PDI) below 0.2, and sizes ranging from 100 to 250 nm. Surface modifications with alginate, chitosan, or PEG yielded distinct zeta potentials (from −25 to +15 mV), mimicking a spectrum of mucoadhesive and mucopenetrative behaviors. Cytotoxicity assessments using the MTT assay established that the nanoparticles exhibited mild toxicity (70−100% cell viability) at concentrations up to 100 μg/mL after 24 hours, suggesting suitability for cellular uptake studies.

The in vitro uptake experiments leveraged a monolayer HCEC model integrated with a simulated mucosal solution to approximate the ocular surface environment. To dissect endocytic mechanisms, the researchers incubated cells with nanoparticles in the presence or absence of established pathway inhibitors targeting clathrin-mediated endocytosis, caveolae-mediated endocytosis, macropinocytosis, and phagocytosis. Quantitative uptake analysis was conducted via fluorescence imaging, enabling robust comparison of nanoparticle internalization under different experimental conditions (Azadi & David, 2024).

Core Findings and Why They Matter

This study provides several key insights into the mechanisms governing nanoparticle uptake by HCECs:

• Energy-dependent endocytosis is the dominant pathway: Cellular uptake was significantly reduced at low temperatures, confirming an active, energy-dependent process.
• Particle size and surface chemistry dictate uptake efficiency: Among tested formulations, 100 nm PLGA nanoparticles and PEG-PLGA-150 nanoparticles exhibited the highest uptake, indicating that both size reduction and PEGylation enhance internalization.
• Multiple endocytic routes contribute: Inhibitor studies revealed that macropinocytosis and caveolae-mediated endocytosis are the primary pathways, while clathrin-mediated endocytosis contributes to a lesser extent. Phagocytosis was not involved for nanoparticles within the studied range of sizes and surface chemistries.

These findings have direct implications for the design of ocular drug delivery systems. By tailoring nanoparticle size and surface chemistry, it is possible to preferentially engage uptake mechanisms that enhance corneal penetration and drug bioavailability, potentially reducing the need for higher dosing or repeated administration. This mechanistic understanding supports the rational development of next-generation ophthalmic therapeutics.

Comparison with Existing Internal Articles

The mechanistic insights from the reference study align with broader trends in endocytosis research. For example, internal resources such as "Dynasore: Benchmark Dynamin GTPase Inhibitor for Endocytosis Research" emphasize the utility of small molecule inhibitors in dissecting endocytic pathways. Dynasore, a noncompetitive dynamin GTPase inhibitor, has been widely used to study clathrin- and caveolae-mediated endocytosis, as well as synaptic vesicle endocytosis inhibition. The current study extends these principles to the context of ocular surface barriers, demonstrating that chemical inhibition (e.g., with agents like Dynasore) provides direct evidence for the roles of specific endocytic routes in nanoparticle uptake.

Additionally, the findings complement observations in "Clathrin-Mediated Endocytosis in Grass Carp Reovirus Entry", where dynamin-dependent pathways were crucial for viral entry, underscoring the generalizability of these mechanisms across diverse biological systems. The use of small molecule inhibitors to parse these pathways is thus a cornerstone technique in both basic and translational research.

Limitations and Transferability

Despite the valuable mechanistic insights, certain limitations must be considered. The study employs an in vitro HCEC model, which, while physiologically relevant, may not fully recapitulate the complexity of in vivo ocular surfaces, including dynamic tear film turnover and immune surveillance. Additionally, the focus on PLGA-based nanoparticles and specific surface modifications constrains direct extrapolation to other nanoparticle chemistries or larger particle sizes. The absence of in vivo validation or pharmacokinetic endpoints also limits conclusions about clinical translation. Nevertheless, the findings provide a rigorous framework for rational nanoparticle design and suggest clear experimental strategies for further investigation in more complex models.

Protocol Parameters

• Nanoparticle synthesis: Emulsion-solvent evaporation method; ensure monodispersity (PDI < 0.2).
• Surface modification: Use alginate, chitosan, or PEG for mucoadhesion/mucopenetration studies.
• Particle size range: 100–250 nm for optimal corneal uptake assessment.
• Cytotoxicity assay: MTT assay after 24 h incubation at up to 100 μg/mL.
• Uptake studies: Monolayer HCECs with simulated mucosal solution; consider temperature controls for energy-dependence verification.
• Pathway inhibition: Apply established inhibitors for clathrin-, caveolae-, and macropinocytosis as controls.

Research Support Resources

For researchers aiming to dissect endocytic mechanisms in ocular or other cellular systems, chemical inhibitors such as Dynasore (SKU A1605) are validated tools for reversible, dose-dependent inhibition of dynamin GTPases. According to the product information, Dynasore has an IC50 of approximately 15 µM and is effective in blocking dynamin-mediated endocytosis in cellular models. Its application can help clarify the contributions of dynamin-dependent pathways in nanoparticle uptake, vesicle trafficking, or signal transduction studies, as highlighted in both the reference study and internal articles. For optimal results, refer to manufacturer guidelines for solubility and storage, and consider integrating Dynasore into your workflow to complement genetic or imaging-based approaches.